US5120534A
Expired / Lapsed
US
⏱️ 0.0 years remaining
IL-1α derivatives and medicament for treating thrombocytopenia
Assignee: Otsuka Pharmaceutical Co Ltd
•
Filing: 1989-07-28
•
Granted: 1992-06-09
•
Expires: 2009-07-28
Abstract
Abstract The present invention provides a medicament for treating thrombocytopenia comprising as an active component at least one polypeptide selected from IL-1 and derivative thereof and a IL-1α derivative having an amino acid sequence of the formula (α) which is so modified as to fulfill at least one of the requirements of: deletion of the 16-position Arg; replacement of the 16-position Arg by another amino acid residue; deletion of the sequence of the 1-position Ser to the 14-position Phe and deletion of the amino acid sequence of the 1-position Ser to the 15-position Met.
Inventors
- 👤 Yoshikatsu Hirai
- 👤 Satoru Nakai
- 👤 Koutoku Aihara
- 👤 Kazuyoshi Kawai
- 👤 Mayumi Kaneta
- 👤 Takashi Kamogashira
- 👤 Yoshihiro Masui
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-09 16:33
CPC Classifications
C; C07; C07K; C07K14/00; C07K14/435; C07K14/52; C07K14/54; C07K14/545; A; A61; A61K; A61K38/00
Claims Analysis
Total Claims: 7
Claim 1
Independent Claim
33 words
A method for treating thrombocytopenia comprising administering, to a subject afflicted with thrombocytopenia, as an active component, a pharmaceutically effective amount of at least one polypeptide selected from interleukin-1 (IL-1) and derivatives thereof.
Claim 2
Independent Claim
33 words
A method for treating thrombocytopenia comprising administering, to a subject afflicted with thrombocytopenia, as an active component, a pharmaceutically effective amount of at least one polypeptide selected from interleukin-1 (IL-1) and derivatives thereof.
Claim 3
Dependent Claim
15 words
A method as defined in claim 1 wherein the active component is an IL-1α derivative.
Claim 4
Dependent Claim
96 words
A method as defined in claim 2 wherein the IL-1α derivative has an amino acid sequence represented by the formula (α): ##STR10## in which X and Y are α-amino acid residues constituting human proteins; and wherein said derivative is so modified as to fulfill at least one of the requirements of: deletion of the 16-position Arg; replacement of the 16-position Arg by another amino acid residue; deletion of the sequence of the 1-position Ser to the 14-position Phe and deletion of the amino acid sequence of the 1-position of the 1-position Ser to the 15-position Met.
Claim 5
Dependent Claim
15 words
A method as defined in claim 1 wherein the active component is an IL-1β derivative.
Claim 6
Dependent Claim
32 words
A method as claimed in claim 1, wherein said IL-1 derivative is IL-1α (36D.141S) wherein Asn at the 36-position is replaced by Asp and Cys at the 141-position is replaced by Ser.
Claim 7
Dependent Claim
22 words
A method as claimed in claim 1, wherein said pharmaceutically effective amount is about 0.01 μg to about 10 mg per day.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1995-06-09 | 1995-12-09 | 1996-06-09 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1999-06-09 | 1999-12-09 | 2000-06-09 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2003-06-09 | 2003-12-09 | 2004-06-09 | $7700.00 | Window Closed / Lapsed |